Trypanosoma cruzi infection beats the B-cell compartment favouring parasite establishment: Can we strike first?

Scandinavian Journal of Immunology

Volumn 66, Issue 2-3, 2007, Pages 137-142

  Acosta Rodriguez, E V ^a   Zuniga, E I ^a   Montes, C L ^a   Merino, M C ^a   Bermejo, D A ^a   Amezcua Vesely, Maria Carolina ^a   Motran, C C ^a   Gruppi, A ^a  

^a UNIVERSIDAD NACIONAL DE CÓRDOBA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; FAS ANTIGEN; FAS LIGAND; GALECTIN 3; INTERLEUKIN 4; LYMPHOCYTE ANTIBODY;

ANTIGEN PRESENTING CELL; APOPTOSIS; B LYMPHOCYTE; BONE MARROW; CELL MATURATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CYTOLOGY; DISEASE COURSE; HOMEOSTASIS; HOST PARASITE INTERACTION; HOST RESISTANCE; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOREGULATION; IN VIVO STUDY; INFECTION; LABORATORY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PARASITE VIRULENCE; POLYCLONAL ACTIVATION; PRIORITY JOURNAL; REVIEW; SPLEEN; T LYMPHOCYTE; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS;

EID: 34447559900     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01968.x     Document Type: Review

References (60)

1. Moncayo A. Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries. Mem Inst Oswaldo Cruz 2003 98 : 577 581.
2. Riarte A, Luna C, Sabatiello R et al. Chagas disease in patients with kidney transplants: 7 years of experience. Clin Infect Dis 1999 29 : 561 7.
3. Castro JA, de Mecca MM, Bartel LC. Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis). Hum Exp Toxicol 2006 25 : 471 9.
4. Kierszenbaum F. Views on the autoimmunity hypothesis for Chagas disease pathogenesis. FEMS Immunol Med Microbiol 2003 37 : 1 11.
5. Andrade ZA Pathogenesis of Chagas' disease. Res Immunol 1991 142 : 126 9.
6. Brener Z. Chagas disease and the nervous system. PAHO Scientific 1994 547 : 30 46.
7. Brener Z, Gazinelli RT. Immunological control of Trypanosoma cruzi infection and pathogenesis of Chagas' disease. Int Arch Allergy Immunol 1997 114 : 103 10.
8. Zuniga E, Acosta-Rodriguez E, Merino MC, Montes C, Gruppi A. Depletion of immature B cells during Trypanosoma cruzi infection: involvement of myeloid cells and the cyclooxygenase pathway. Eur J Immunol 2005 35 : 1849 58.
9. Binder D, Fehr J, Hengartner H, Zinkernagel RM. Virus-induced transient bone marrow aplasia: major role of interferon-alpha/beta during acute infection with the noncytopathic lymphocytic choriomeningitis virus. J Exp Med 1997 185 : 517 30.
10. Hilleman MR. strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc Natl Acad Sci U.S.A 2004 101 : 14560 66.
11. Lenardo M, Chan KM, Hornung F et al. Mature T lymphocyte apoptosis - immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol 1999 17 : 221 253.
12. Barcinski MA, DosReis GA. Apoptosis in parasites and parasite induced apoptosis in the host immune system: a new approach to parasitic diseases. Braz J Med Biol Res 1999 32 : 395 401.
13. Marcondes MC, Borelli P, Yoshida N, Russo M. Acute Trypanosoma cruzi infection is associated with anemia, thrombocytopenia, leukopenia, and bone marrow hypoplasia: reversal by nifurtimox treatment. Microbes Infect 2000 2 : 347 52.
14. Minoprio P, Bandeira A, Pereira P, Mota Santos T, Coutinho A. Preferential expansion of Ly-1 B and CD4- CD8- T cells in the polyclonal lymphocyte responses to murine T. cruzi infection. Int Immunol 1989a 1 : 176 84.
15. Freire-de-Lima C, Pecanha LM, Dos Reis GA. Chronic experimental Chagas' disease: functional syngeneic T-B-cell cooperation in vitro in the absence of an exogenous stimulus. Infect Immun 1996 64 : 2861 6.
16. Minoprio P, Itohara S, Heusser C, Tonegawa S, Coutinho A. Immunobiology of murine T. cruzi infection: the predominance of parasite-nonspecific responses and the activation of TCRI T cells. Immunol Rev 1989b 112 : 183 207.
17. Reina-San-Martin B, Degrave W, Rougeot C et al. A. B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. Nat Med 2000a 6 : 890 7.
18. Montes CL, Zuniga EI, Vazquez J, Arce C, Gruppi A. Trypanosoma cruzi mitochondrial malate dehydrogenase triggers polyclonal B-cell activation. Clin Exp Immunol 2002 127 : 27 36.
19. Montes CL, Acosta-Rodriguez EV, Mucci J, Zuniga EI, Campetella O, Gruppi A A. Trypanosoma cruzi antigen signals CD11b+ cells to secrete cytokines that promote polyclonal B cell proliferation and differentiation into antibody-secreting cells. Eur J Immunol 2006 36 : 1474 85.
20. Minoprio P, Burlen O, Pereira P et al. Most B cells in acute Trypanosoma cruzi infection lack parasite specificity. Scand J Immunol 1988 28 : 553 61.
21. Kierszenbaum F, Howard JG. Mechanisms of resistance against Trypanosoma cruzi infection: the importance of antibodies and antibody forming capacity in biozzi high and low responder mice. J Immunol 1976 116 : 1208 14.
22. Rottenberg ME, Cardoni RL, Segura EL. Involvement of L3T4+, LYT2.2+ T cell subsets and non-T cells in the resistance of mice against Trypanosoma cruzi infection. Int J Parasitol 1990 20 : 397 400.
23. Almeida IC, Milani SR, Gorin PA, Travassos LR. Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies. J Immunol 1991 146 : 2394 400.
24. Krettli AU, Brener Z. Protective effects of specific antibodies in Trypanosoma cruzi infection. J Immunol 1976 116 : 755 61.
25. Rodriguez de Cuna C, Kierszenbaum F, Wirth JJ. Binding of the specific ligand to Fc receptors on Trypanosoma cruzi increases the infective capacity of the parasite. Immunology 1991 72 : 114 20.
26. Brener Z. Why vaccines do not work in Chagas' disease. Parasitol Today 1986 2 : 196 202.
27. Minoprio P, Coutinho A, Spinella S, Hontebeyrie-Joskowicz M. Xid immunodeficiency imparts increased parasite clearance and resistance to pathology in experimental Chagas' disease. Int Immunol 1991 3 : 427 33.
28. Hayakawa K, Hardy RR, Herzenberg LA. Peritoneal Ly-1 B cells: genetic control, autoantibody production, increased lambda light chain expression. Eur J Immunol 1986 16 : 450 6.
29. Tarleton RL. Chagas disease: a role for autoimmunity? Trends Parasitol 2003 19 : 447 51.
30. Reina-San-Martin B, Cosson A, Minoprio P. Lymphocyte polyclonal activation: a pitfall for vaccine design against infectious agents. Parasitol Today 2000b 16 : 62 7.
31. Minoprio P, Andrade L, Lembezat MP, Ozaki LS, Coutinho A. Indiscriminate representation of VH-gene families in the murine B lymphocyte responses to Trypanosoma cruzi. J Immunol 1989 142 : 4017 21.
32. Motran CC, Cerban FM, Rivarola W, Iosa D, Vottero de Cima E. Trypanosoma cruzi: immune response and functional heart damage induced in mice by the main linear B-cell epitope of parasite ribosomal P proteins. Exp Parasitol 1998 88 : 223 30.
33. Giordanengo L, Maldonado C, Rivarola HW et al. Induction of antibodies reactive to cardiac myosin and development of heart alterations in cruzipain-immunized mice and their offspring. Eur J Immunol 2000 30 : 3181 9.
34. Girones N, Cuervo H, Fresno M. Trypanosoma cruzi-induced molecular mimicry and Chagas' disease. Curr Top Microbiol Immunol 2005 296 : 89 123.
35. Cunningham DS, Kuhn RE, Rowland EC. Suppression of humoral responses during Trypanosoma cruzi infections in mice. Infect Immun 1978 22 : 155 60.
36. Zúñiga E, Motran C, Montes CL, Diaz FL, Bocco JL, Gruppi A. Trypanosoma cruzi-induced immunosuppression: B cells undergo spontaneous apoptosis and lipopolysaccharide (LPS) arrests their proliferation during acute infection. Clin Exp Immunol 2000 119 : 507 15.
37. Lopes MF, DosReis GA. Trypanosoma cruzi-induced immunosuppression: selective triggering of CD4+ T-cell death by the T-cell receptor-CD3 pathway and not by the CD69 or Ly-6 activation pathway. Infect Immun 1996 64 : 1559 64.
38. Majumder S, Kierszenbaum F. Mechanisms of Trypanosoma cruzi-induced down-regulation of lymphocyte function.Inhibition of transcription and expression of IL-2 receptor gamma (p64IL-2R) and beta (p70IL-2R) chain molecules in activated normal human lymphocytes. J Immunol 1996 156 : 3866 74.
39. Zúñiga E, Motran CC, Montes CL, Yagita H, Gruppi A. Trypanosoma cruzi infection selectively renders parasite-specific IgG+ B lymphocytes susceptible to Fas/Fas ligand-mediated fratricide. J Immunol 2002 15 168 : 3965 73.
40. Van Parijs L, Abbas AK. Homeostasis and self-tolerance in the immune system: turning lymphocytes off. Science 1998 280 : 243 8.
41. Freire-de-Lima CG, Nascimento DO, Soares MB et al. Uptake of apoptotic cells drives the growth of a pathogenic trypanosome in macrophages. Nature 2000 403 : 199 203.
42. Mamula MJ, Janeway CA Jr. Do B cells drive the diversification of immune responses? Immunol Today 1993 14 : 151 2.
43. Kurt-Jones EA, Liano D, HayGlass KA, Benacerraf B, Sy MS, Abbas AK. The role of antigen-presenting B cells in T cell priming in vivo. Studies of B cell-deficient mice. J Immunol 1988 140 : 3773 8.
44. Janeway CA Jr., Bottomly K. Signals and signs for lymphocyte responses. Cell 1994 76 : 275 85.
45. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol 1995 155 : 3734 41.
46. Rossi-Bergmann B, Muller I, Godinho EB. TH1 and TH2 T-cell subsets are differentially activated by macrophages and B cells in murine leishmaniasis. Infect Immun 1993 61 : 2266 9.
47. Hollsberg P, Batra V, Dressel A, Hafler DA. Induction of anergy in CD8 T cells by B cell presentation of antigen. J Immunol 1996 157 : 5269 76.
48. Adorini L, Guery JC, Ria F, Galbiati F. B cells present antigen to CD4+ T cells, but fail to produce IL-12. Selective APC for Th2 cell development? Ann N Y Acad Sci 1997 815 : 401 11.
49. Croft M, Joseph SB, Miner KT. Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells. J Immunol 1997 159 : 3257 65.
50. Zuniga E, Rabinovich GA, Iglesias MM, Gruppi A. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J Leukoc Biol 2001 70 : 73 9.
51. Rabinovich GA, Baum LG, Tinari N et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002 23 : 313 20.
52. Tarleton RL. Depletion of CD8+ T cells increases susceptibility and reverses vaccine-induced immunity in mice infected with Trypanosoma cruzi. J Immunol 1990 144 : 717 24.
53. Rottenberg ME, Cardoni RL, Sinagra A et al. Trypanosoma cruzi: T-cell-dependent mechanisms of resistance during chronic infection. Exp Parasitol 1991 73 : 127 36.
54. Abrahamsohn IA, Coffman RL. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection. Exp Parasitol 1996 84 : 231 44.
55. Bafica A, Santiago HC, Goldszmid R, Ropert C, Gazzinelli RT, Sher A. Cutting edge: TLR9 and TLR2 signaling together account for MyD88-dependent control of parasitemia in Trypanosoma cruzi infection. J Immunol 2006 177 : 3515 19.
56. Minoprio P, el Cheikh MC, Murphy E et al. Xid-associated resistance to experimental Chagas' disease is IFNg dependent. J Immunol 1993 151 : 4200 09.
57. Reed S. In vivo administration of recombinant IFNg induces macrophages activation and prevents acute disease, immunosuppression, and death in experimental Trypanosoma cruzi infection. J Immunol 1988 140 : 4342 50.
58. Acosta Rodriguez EV, Zuniga E, Montes CL, Gruppi A. Interleukin-4 biases differentiation of B cells from Trypanosoma cruzi-infected mice and restrains their fratricide: role of Fas ligand down-regulation and MHC class II-transactivator up-regulation. J Leukoc Biol 2003 73 : 127 36.
59. Knodel M, Kuss AW, Berberich I, Schimpl A. Blimp-1 over-expression abrogates IL-4- and CD40-mediated suppression of terminal B cell differentiation but arrests isotype switching. Eur J Immunol 2001 31 : 1972 80.
60. Acosta-Rodriguez EV, Montes CL, Motran CC et al. Galectin-3 mediates IL-4-induced survival and differentiation of B Cells: Functional cross-talk and implications during Trypanosoma cruzi Infection. J Immunol 2004 172 : 493 502.